Stapokibart injection for atopic dermatitis in adults
Treatments studied
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This study tests a new injection medicine called Stapokibart for treating atopic dermatitis (a chronic skin condition causing itching and inflammation). Your doctor has already decided this medicine might help you before you joined the study.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- Your doctor independently decided you should try Stapokibart for your atopic dermatitis
- You do not have a known allergy to Stapokibart
- You are not currently enrolled in another treatment study and do not plan to be
- You do not have blood cancers (hematologic malignancies)
- If you are a woman, you are not pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental medication (Stapokibart) for children ages 2 to 11 with moderate-to-severe eczema that hasn't improved with topical creams. The goal is to see if the new treatment can help control their symptoms.
Stapokibart is a new injection that works on a key pathway involved in allergy symptoms. This study will test if this once-every-two-week shot can help reduce runny nose, sneezing, and itchy eyes in people with allergic rhinitis (hay fever).
This study tests a new injection called Stapokibart for people with seasonal allergic rhinitis (hay fever triggered by pollen or mold). The goal is to see if it helps control symptoms like sneezing, runny nose, and itchy eyes.
This trial tests a new injectable drug, Stapokibart, for people with moderate to severe bullous pemphigoid, a blistering skin condition. The goal is to see if the drug can help reduce blistering and itching.
This trial tests a medicine called Stapokibatrt in children with atopic dermatitis (eczema). It is for kids who already completed the main study and may help manage their skin condition.
This study tests a new injectable medication called stapokibart to help teenagers with seasonal allergic rhinitis (hay fever). The goal is to see if this treatment reduces allergy symptoms like sneezing, congestion, and itchy eyes during allergy season.
Hear when a new Atopic Dermatitis (AD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.